Trial reportPloS one2025
Platelet-to-Neutrophil Ratio and Efficacy of Remote Ischemic Conditioning in Acute Ischemic Stroke.
Trial report in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03740971 (Remote Ischemic Conditioning for Acute Moderate Ischemic Stroke), which is not on this map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Remote Ischemic Conditioning for Acute Moderate Ischemic Stroke (RICAMIS): a Prospective, Random, Open Label, Blinded End Point, Multi-center Study
Who cites it
3 citing papers in PubMed.
- Biomarkers of Remote Ischaemic Conditioning in Stroke and Cerebral Small Vessel Disease: A Narrative Review.NeuroSci · 2026Review
- Association of platelet to HDL-C ratio with short-term mortality in critically ill intracerebral hemorrhage patients: a MIMIC-IV analysis.Scientific reports · 2026Article
- Platelet-to-neutrophil ratio and in-hospital mortality in pneumonia patients receiving glucocorticoid therapy: a multicenter retrospective cohort study.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRemote ischemic conditioning (RIC) has been proven to improve neurologic function after stroke in RICAMIS trial. Aggravated thrombosis and inflammatory through interaction between platelet and immune cells affected the prognosis of stroke. We conducted an exploratory secondary analysis of RICAMIS to investigate whether platelet-to-neutrophil ratio (PNR) predicted efficacy of RIC in stroke.
methodsPatients without protocol violation and with baseline blood routine examination from the full analysis set were included and divided into low PNR and high PNR subgroups. The primary outcome was 90-day excellent functional outcome defined as modified Rankin Scale score of 0-1. Compared with usual care alone, we investigated efficacy of RIC treatment in each PNR subgroup and their interaction.
resultsOf 1679 patients, 360 were assigned to low PNR and 1319 into high PNR. Compared with usual care alone, RIC treatment was associated with higher likelihood of 90-day excellent functional outcome across PNR, but significantly different in low PNR (60.9% versus 50.3%, adjusted RD, 11.3%; 95% CI, 1.1% to 21.5%; P =0.03) and not significantly different in high PNR (70.8% versus 65.3%, adjusted RD, 3.9%; 95% CI, -1.2% to 8.9%; P =0.13). No significant interaction was found (P =0.96).
conclusionsThis study firstly investigated the association between PNR at admission and efficacy of RIC treatment in stroke. With respect to long-term functional outcomes, patients benefited from RIC treatment regardless of PNR, but the benefit increased when level of PNR at admission was lower. Trial registration ClinicalTrials.gov Identifier: NCT03740971.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.